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Abstract
Introduction The lymphotoxin-beta receptor (LTR) pathway is
important in the development and maintenance of lymphoid
structures. Blocking this pathway has proven beneficial in
murine models of autoimmune diseases such as diabetes and
rheumatoid arthritis. The aim of this study was to determine the
effects of LTR pathway blockade on Sjögren syndrome (SS)-
like salivary gland disease in non-obese diabetic (NOD) mice.
Methods The course of SS-like disease was followed in NOD
mice that were given lymphotoxin-beta receptor-immunoglobulin
fusion protein (LTR-Ig) starting at 9 weeks of age. Treatment
was given as a single weekly dose for 3, 7, or 10 weeks. Age-
matched NOD mice treated with mouse monoclonal IgG1, or
not treated at all, were used as controls. The severity of
inflammation, cellular composition, and lymphoid neogenesis in
the submandibular glands were determined by
immunohistochemistry. Mandibular lymph nodes were also
studied. Saliva flow rates were measured, and saliva was
analyzed by a multiplex cytokine assay. The salivary glands were
analyzed for CXCL13, CCL19, and CCL21 gene expression by
quantitative polymerase chain reaction.
Results Treatment with LTR-Ig prevented the increase in size
and number of focal infiltrates normally observed in this SS-like
disease. Compared with the controls, the submandibular glands
of LTR-Ig-treated mice had fewer and smaller T- and B-cell
zones and fewer high endothelial venules per given salivary
gland area. Follicular dendritic cell networks were lost in LTR-
Ig-treated mice. CCL19 expression was also dramatically
inhibited in the salivary gland infiltrates. Draining lymph nodes
showed more gradual changes after LTR-Ig treatment. Saliva
flow was partially restored in mice treated with 10 LTR-Ig
weekly injections, and the saliva cytokine profile of these mice
resembled that of mice in the pre-disease state.
Conclusions Our findings show that blocking the LTR
pathway results in ablation of the lymphoid organization in the
NOD salivary glands and thus an improvement in salivary gland
function.
Introduction
Sjögren syndrome (SS) is a chronic autoimmune disorder
characterized by lymphocytic infiltrates of the exocrine glands.
Patients present clinical symptoms of dry eyes and dry mouth.
The exocrinopathy may occur alone (primary SS) or in associ-
ation with another autoimmune disorder (secondary SS) such
as rheumatoid arthritis or systemic lupus erythematosus [1].
Inflammatory reactions in the lacrimal and salivary glands withPage 1 of 12
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tion, are reported in SS patients [2-5].
The lymphotoxins (LT and LT) and LIGHT (a cytokine
homologous to LTs that shows inducible expression and com-
petes with herpes simplex virus glycoprotein D for herpes virus
mediator [HVEM], a receptor induced on T cells) and their
receptors are part of the tumor necrosis factor (TNF) super-
family. LT exists in both secreted and membrane-bound
forms. The membrane-bound form is a complex of LT and
LT [6], forming in humans a predominant LT12 heteromer
[7]. This ligand binds the LT receptor (LTR) [8] along with
LIGHT [9]. For a detailed review of LT and LIGHT signaling,
see [10].
The LTR signaling pathway is important in the development
of organized lymphoid structures [10-18]. In the differentiated
tissue, the LTR signaling pathway is involved in the control of
expression of chemokines and adhesion molecules that aid in
the movement of lymphocytes and in their compartmentaliza-
tion into T- and B-cell zones, high endothelial venule (HEV)
development, and follicular dendritic cell (FDC) network for-
mation and in the positioning and numbers of dendritic cells
[19]. This signaling pathway is also crucial in lymphoid neo-
genesis at sites of inflammation [20]. Lymphoid neogenesis is
reported in human chronic inflammatory diseases (including
SS) and associated mouse models (reviewed in [21,22]).
The efficacy of LTR pathway blockade (that is, the blocking
of activation of LTR by either of its ligands via the pharmaco-
logical inhibitor LTR-immunoglobulin fusion protein [LTR-
Ig]) has been studied in many murine disease models
(reviewed in [19]), and a human version was used in rheuma-
toid arthritis clinical trials [13].
In non-obese diabetic (NOD) mice, treatment with LTR-Ig
prevented insulin-dependent diabetes mellitus (IDDM) and
reversed insulitis [23,24]. In addition, soluble LTR-Ig trans-
gene expression on the NOD background blocked diabetes
development [25]. In addition to spontaneously developing
IDDM, the NOD mouse spontaneously develops lymphocytic
infiltrates in the exocrine glands, with associated glandular
dysfunction [26]. Although the Idd3 and Idd5 susceptibility
loci for diabetes have a role in the development of sialadenitis,
the IDDM and sialadenitis are two independent autoimmune
events [27-29].
The aim of the present study was to analyze the effects of LT/
LIGHT axis blockade by the pharmacological inhibitor LTR-Ig
on SS-like salivary gland disease in female NOD mice, intro-
ducing the inhibitor prior to the development of the SS-like dis-
ease. The study confirmed that blocking the LTR pathway
results in ablation of the lymphoid organization in the NOD sal-
ivary glands, leading to an improvement in salivary gland func-
tion.
Materials and methods
Animals and treatment protocols
Female NOD/LtJ mice were purchased from The Jackson Lab-
oratory (Bar Harbor, ME, USA) and maintained in accordance
with standard animal housing and welfare guidelines. The pro-
tocol is shown in Figure 1a. In summary, eight mice that were
not treated (NT) were euthanized at 9 weeks (NT9 group) and
formed the baseline of the experiment. Beginning at 9 weeks
of age, groups of eight mice were given weekly intraperitoneal
injections of 100 g of either LTR-Ig (murine receptor fused
to mouse IgG1, which has been described previously [30]) or
mouse monoclonal IgG1 (MOPC 21) for 3, 7, and 10 weeks.
Mice were then euthanized 1 week after the last injection (that
is, at 12, 16, or 19 weeks). The LTR-Ig-treated mice are sub-
sequently referred to as LT12, LT16, and LT19 and the MOPC
21-treated ones as MO12, MO16, and MO19, respectively.
Groups of age-matched control mice that were NT (with either
LTR-Ig or MOPC 21) were also investigated and are subse-
quently referred to as NT12, NT16, and NT19. The experimen-
tal protocol (research number 2006012BB) was approved by
the National Animal Research Authority of Norway.
Diabetes monitoring
The mice were monitored weekly for changes in weight. On
the day of euthanasia, blood glucose was measured after 2
hours of fasting (with water ad libitum) using the HemoCue
Glucose 201 RT test kit (HemoCue Norge, Oslo, Norway).
Salivary gland function analysis
On the day of euthanasia, a subcutaneous injection of a com-
bination of ketamine and medetomidine hydrochloride (0.15
mL per 20 g of body weight) was used to anaesthetize the
mice. Saliva secretion was stimulated by intraperitoneal pilo-
carpine in saline (0.1 mL per 20 g of body weight), collected
for 10 minutes by a pipette, and transferred to pre-weighed
microtubes. The volume of the saliva sample was determined
and standardized against the weight of the individual mouse.
The saliva samples were then frozen at -80°C.
Multiplex cytokine analysis of saliva
Saliva samples were analyzed for cytokines using a mouse
cytokine twenty-plex kit (catalog number LMC006, BioSource;
Invitrogen Corporation, Carlsbad, CA, USA). The instructions
of the manufacturer were adhered to. The assay was meas-
ured by a Luminex 100™ instrument (Luminex Corporation,
Austin, TX, USA) and analyzed using StarStation 2.0 software
(Applied Cytometry Systems, Sacramento, CA, USA).
Salivary gland inflammation analysis
Submandibular and sublingual salivary glands were excised
and either snap-frozen in isopentane by liquid nitrogen and
stored at -80°C or placed in 4% formalin, left overnight, and
processed under standard techniques to obtain paraffin
blocks. The submandibular glands of all of the mice were
examined histologically after hematoxylin-and-eosin staining ofPage 2 of 12
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metrically analyzed using a Leica DMLB light microscope
(Leica, Wetzlar, Germany) connected to an Olympus Color
View III camera (Olympus, Tokyo, Japan) and AnalySIS soft-
ware (Soft Imaging System, Münster, Germany). The focus
score [31] (number of foci made up of at least 50 mononuclear
cells per square millimeter of glandular tissue) and ratio index
[32] (ratio of the area of inflammation to the total area of the
gland) were determined.
Antibodies
The antibodies used were anti-B220, rat IgG2B, clone RA3-
6B2 (R&D Systems, Minneapolis, MN, USA) (stains B cells);
anti-CD4, rat IgG2B, clone YTS191.1 (Dako Denmark A/S,
Glostrup, Denmark) (stains T cells); anti-CD21/CD35, clone
7G6 (BD Pharmingen, San Diego, CA, USA) (stains FDCs);
anti-peripheral (lymph) node addressin (anti-PNAd) carbohy-
drated epitope, clone MECA-79 (BD Pharmingen) (stains
HEVs); anti-CXCL13 goat IgG, lot numbers COZ025081 and
COZ026061 (R&D Systems); and anti-CCL19 goat IgG, lot
number BUL026021 (R&D Systems). The avidin-biotin com-
plex technique was used for the immunohistochemistry analy-
sis as described previously [32]. Frozen and paraffin sections
of salivary glands and mandibular lymph nodes (processed in
same manner as indicated above for salivary glands) were ana-
lyzed.
Analysis of T- and B-cell zones and high endothelial 
venules
The submandibular glands were examined histologically by
authors MKG and KS in a blinded fashion after immunohisto-
chemical single-staining with CD4 (stains T cells), B220
(stains B cells), and PNAd (stains HEVs) and morphometri-
cally analyzed as stated above. The ratio of the zone of T-cell
aggregates or B-cell aggregates to the total area of the sub-
mandibular gland was determined. Isolated stained cells were
not included in this analysis. The number of HEVs per given
submandibular gland area was also analyzed.
Figure 1
Experimental protocol and the effect of lymphotoxin-beta receptor-immunoglobulin fusion protein (LTR-Ig) treatment on blood glucose levels and on submandibu ar gland inflammation
submandibular gland inflammation. (a) A weekly injection (i) of either LTR-Ig (LT) or mouse monoclonal IgG1 (MOPC 21) (MO). An isotype-
matched control Ig was administered. Age-matched mice that were not treated (NT) were also examined. Saliva flow rate measurements were per-
formed, and the mice were then euthanized and salivary glands were harvested (†). (b) Blood glucose levels of individual mice in the experiment. 
Horizontal lines indicate the median. At 19 weeks, the LTR-Ig-treated group blood glucose level was significantly lower than that of the age-
matched untreated mice (P < 0.001). Symbols refer to individual mice treated with LTR-Ig (), MOPC 21 (❍), or no treatment (). Each symbol 
indicates data from one mouse, and data were obtained on the day of euthanasia. The ratio index (c) and focus score (d) were used to analyze the 
level of inflammation in the submandibular glands. Each group comprised seven or eight mice. Bars indicate the mean and the standard error of the 
mean.Page 3 of 12
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Dissected submandibular glands from seven or eight mice
were placed in RNA later® (Ambion, Inc., Austin, TX, USA) at
4°C overnight before being frozen at -80°C until use. Organs
were disrupted in TRIzol® Reagent (Invitrogen Corporation).
RNA was extracted using RNeasy (Qiagen Inc., Valencia, CA,
USA). RNA was DNase-treated and cDNA was prepared
using a cDNA archive kit (Applied Biosystems, Foster City,
CA, USA). Quantitative polymerase chain reaction (QPCR)
was performed as described previously [33]. All RNA samples
were run in quadruplicate. The data were normalized to glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) as an
endogenous control. QPCR primers and probes were as fol-
lows: CXCL13: forward GTAAAACGCAGGCTTCCAAAA,
reverse GATGGCATTGCACCAGCTT, and FAM probe
AGTCTCCAGAAGGTTC; CCL19: forward CCTCG-
GCCTCTCAGATTCTTG, reverse GGCAGGCCACAGA-
GAGTGA, and FAM probe CACACAGTCTCTCAGGCT; and
CCL21: forward GGGCTGCAAGAGAACTGAACA, reverse
GGCGGGCTACTGGGCTAT, and FAM probe
ACACAGCCCTCAAGAG.
Serum analysis for LTR-Ig levels by enzyme-linked 
immunosorbent assay
A 96-well plate was coated with hamster anti-murine LTR
ACH6 (Biogen Idec, Cambridge, MA, USA) and incubated
overnight. The plate was blocked with 1% bovine serum albu-
min (BSA) in phosphate-buffered saline (PBS). Sera, at dilu-
tion 1:900 in 1% BSA in PBS, were added to the wells and
incubated for 1 hour. Peroxidase-conjugated donkey anti-
mouse IgG (code number 715-036-150; Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA, USA) was then
incubated for 35 minutes. Samples were run in duplicate.
Serial dilutions of LTR-Ig were used to construct the stand-
ard curve. Plates were washed with PBS (pH 7.0) with 0.05%
Tween. Absorbance values were measured by a Multiskan®
microplate photometer (Labsystems Inc., Franklin, MA, USA)
and analyzed by Ascent software (Thermo Fisher Scientific
Inc., Waltham, MA, USA).
Statistics
Parametric data were analyzed using one-way between-
groups analysis of variance (ANOVA) with Tukey HSD (hon-
estly significant difference) post hoc test and the Student t
test. Two-way between-groups ANOVA was undertaken for
specific comparisons of LTR-Ig and MOPC 21 treatment on
blood glucose levels, inflammation, and saliva flow rates. The
Mann-Whitney U test was used for non-parametric data. Pear-
son's correlation was used to describe linear relationships.
Saliva cytokines were Z-standardized. SPSS version 15.0
(SPSS Inc., Chicago, IL, USA) was used for these analyses.
The Kruskal-Wallis test and Dunn's multiple comparison test
were used for the LTR-Ig level analysis using GraphPad ver-
sion 4 (GraphPad Software, Inc., San Diego, CA, USA). P val-
ues of less than 0.05 were considered significant.
Results
Effect of LTR-Ig treatment on blood glucose levels
As highlighted in the Introduction, several studies have
reported successful prevention of diabetes development in
NOD mice upon treatment with LTR-Ig. We used the blood
glucose levels as an in-house control to determine the efficacy
of LTR-Ig treatment. Both the number of injections and the
type of treatment (either LTR-Ig or MOPC 21) played a role
in determining the glucose levels, as shown by the significant
interaction effect (P < 0.001). This finding was underscored
by the low glucose levels at 16 weeks in the LT16 group com-
pared with age-matched controls, and at 19 weeks, the LT19
group glucose levels were not only lower than those of the
LT16 group, but also significantly different from those of age-
matched controls (Figure 1b).
LTR-Ig treatment inhibits submandibular gland 
inflammation
Submandibular salivary glands were examined for inflamma-
tion. The ratio index and focus score were used to determine
the level of inflammation and the two methods showed a
strong correlation (r = 0.807, n = 75, P < 0.001). LTR-Ig-
treated groups had reduced levels of inflammation as they
aged and also the lowest inflammation levels compared with
the controls at the different ages at which the mice were exam-
ined (Figure 1c, d). Collectively, the levels of inflammation
increased as the NOD mice aged, with the oldest (19-week-
old) untreated mice (NT19) recording the highest inflammation
in the study (Figure 1c, d). In marked contrast to MOPC 21-
treated and untreated mice, the inflammation levels (focus
score and ratio index) in LTR-Ig-treated mice never differed
significantly from levels of healthy 9-week-old pre-disease
mice. The inflammation levels of the LT19 group were signifi-
cantly different from those of the NT19 group, but the compar-
ison between LT19 and MO19 was not significant (Figure 1c,
d). However, the main effect of treatment (comparing all LTR-
Ig-treated mice with all MOPC 21-treated groups using two-
way between-groups ANOVA) was significant for both ratio
index (P = 0.005) and focus score (P = 0.007).
After establishing that inflammation was indeed inhibited, we
were interested in determining the specific components
affected by the treatment and in establishing a time line for dis-
ease development. For these studies, an average of four mice
per group were randomly selected to represent each treated
group and each age. Tissue sections were prepared and
appropriate antibodies were used to determine the specific
cell phenotypes and structures (Tables 1 and 2).
LTR-Ig treatment reduces the B- and T-cell zones in 
submandibular glands
There were no B-cell zones at the beginning of the experiment
(NT9). These appeared in all of the groups at 12 weeks and
peaked at 16 weeks of age (Figure 2a, b). At 19 weeks, the
LTR-Ig-treated group B-cell zones were almost completelyPage 4 of 12
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group) (Figure 2b and data not shown). Statistical compari-
sons between MOPC 21 and LTR-Ig groups indicate that B-
cell zone ratios were influenced mainly by treatment type (P =
0.011) and number of injections (P = 0.037). Although the
intergroup differences were not statistically significant, T-cell
zones increased with age in the MOPC 21 and untreated
groups but declined with age in the LTR-Ig group (Figure 2a,
c). The B-cell zones were smaller than T-cell zones (see y-axis
of Figure 2a, b). When B-cell zones or T-cell zones were
observed in LTR-Ig-treated mice, these structures were com-
posed of groups of closely packed cells concentrated at one
pole of the infiltrate. Scattered T and B cells were also
observed (Figure 2a).
LTR-Ig treatment inhibits high endothelial venules and 
follicular dendritic cell networks in submandibular 
glands
LTR-Ig treatment inhibited/reversed development of HEVs
(Table 1 and Figure 2a, d). In all of the LTR-Ig-treated mice
examined, only one HEV in one 12-week-old mouse was
observed. FDC networks were first noted at 12 weeks of age
in the untreated mice (NT12). Treatment with LTR-Ig blocked
development of FDC networks in the salivary glands examined
(Table 1 and Figure 3a).
The effect of LTR-Ig treatment on chemokine mRNA 
expression and immunoreactive protein and the 
profound reduction of CCL19 protein
CXCL13 was present in the inflammatory infiltrates of all of the
groups studied except the untreated 9-week-old mice (NT9)
(Table 2 and Figure 3a). Some cells showed membranous
staining but more commonly CXCL13 was noted as a dis-
persed substance within the infiltrates (Figure 3a). CCL19
was demonstrated in the salivary glands at sites of inflamma-
tion, more commonly as a dispersed substance within the infil-
trate (Figure 3a). In some cells, CCL19 membranous staining
was also observed (Figure 3a). CCL19 expression was also
found on ductal and acinar epithelia (Table 2 and Figure 3a).
Unlike CXCL13, CCL19 was not expressed in the infiltrate of
any of the mice treated with LTR-Ig (Table 2). The mRNA
expression levels of CXCL13, CCL19, and CCL21 were also
analyzed, as shown in Figure 3b–d. When we compared the
chemokines in the LTR-Ig-treated mice with those of age-
matched controls or the baseline group (NT9), only CXCL13
was clearly downmodulated.
Table 1
Absolute numbers of mice positive for high endothelial venules 
and follicular dendritic cell networks
High endothelial venules Follicular dendritic cells
Treatment LT MO NT LT MO NT
Age in weeks
9 - - 0/4 - - 0/4
12 1/4 1/4 2/4 0/4 0/4 2/4
16 0/4 4/4 3/4 0/4 1/4 3/4
19 0/4 3/4 2/3 0/4 2/4 1/3
Treatment with either lymphotoxin-beta receptor-immunoglobulin 
fusion protein (LTR-Ig) or mouse monoclonal IgG1 (MOPC 21) was 
started at week 9. Euthanization was carried out 1 week after the last 
injection. Mice receiving either LTR-Ig or MOPC 21 and euthanized 
at 12 weeks of age had received 3 injections, those euthanized at 16 
weeks of age had received 7 injections, and those euthanized at 19 
weeks of age had received 10 injections. -, no mice in these groups; 
LT, mice treated with lymphotoxin-beta receptor-immunoglobulin 
fusion protein; MO, mice treated with mouse monoclonal IgG1; NT, 
mice not treated.
Table 2
Absolute numbers of mice positive for chemokines
CXCL13 CCL19
Treatment LT MO NT LT MO NT
Age in weeks Acini/duct Infiltrate Acini/duct Infiltrate Acini/duct Infiltrate
9 - - 0/4 - - - - 4/4 0/4
12 2/4 1/4 4/4 4/4 0/4 4/4 1/4 4/4 2/4
16 4/4 4/4 4/4 4/4 0/4 4/4 4/4 4/4 3/4
19 2/4 4/4 3/3 3/4 0/4 2/4 2/4 2/3 1/3
Treatment with either lymphotoxin-beta receptor-immunoglobulin fusion protein (LTR-Ig) or mouse monoclonal IgG1 (MOPC 21) was started at 
week 9. Euthanization was carried out 1 week after the last injection. Mice receiving either LTR-Ig or MOPC 21 and euthanized at 12 weeks of 
age had received 3 injections, those euthanized at 16 weeks of age had received 7 injections, and those euthanized at 19 weeks of age had 
received 10 injections. -, no mice in these groups; LT, mice treated with lymphotoxin-beta receptor-immunoglobulin fusion protein; MO, mice 
treated with mouse monoclonal IgG1; NT, mice not treated.Page 5 of 12
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In contrast to the salivary glands where no LTR-Ig-treated
mice had FDC networks, the mandibular lymph nodes were
affected by LTR-Ig treatment in a more gradual manner:
Some disorganized or remnant networks were found in both
LT12 (Figure 4) and LT16, but none was found in LT19 group
(data not shown). The effect of LTR-Ig treatment on CCL19
(Figure 4) was also less dramatic in the mandibular lymph
nodes than in the salivary glands as this chemokine was
expressed in some but not all lymph nodes in the LT16 and
LT19 groups. Whereas HEVs in the salivary glands were very
sensitive to LTR-Ig treatment and were completely cleared in
the LT16 and LT19 groups, HEVs as revealed by MECA-79
staining were diminished in the mandibular lymph nodes
although some HEVs were still visible in the LT12 (Figure 4),
LT16, and LT19 groups. These histological changes to the
lymph nodes resemble those described previously following
LTR-Ig treatment [33]. CXCL13 was expressed in all of the
draining lymph nodes from the LTR-Ig-treated mice. How-
ever, more intense staining was noted in the controls than in
the LTR-Ig-treated mice (Figure 4), indicating the likelihood of
a quantitative difference.
Salivary gland function is partially restored after 
treatment with LTR-Ig
Generally, a subtle dichotomous distribution of saliva flow
rates within each group was observed (Figure 5a). To deter-
mine whether saliva flow rate was restored, all of the groups of
mice were compared with the pre-disease state (that is,
untreated mice euthanized at 9 weeks [NT9]). Overall, the
saliva flow rate declined in all of the groups of NOD mice that
were 9 to 12 weeks old but this decline was not statistically
significant (Figure 5a). At 16 weeks, all three groups had a sig-
nificant decline in saliva flow (Figure 5a). At 19 weeks of age,
Figure 2
Effect of lymphotoxin-beta receptor-immunoglobulin fusion protein (LTR-Ig) treatment on B-cell zones, T-cell zones, and high endothelial venules (HEVs)
(HEVs). (a) Photomicrographs of immunohistochemical staining for B cells, T cells, and HEVs in the submandibular glands. Three or four mice from 
each of the 10 groups were randomly selected for immunohistochemistry. Data shown here are representative examples of control mice (19 weeks 
old) that were not treated (NT19) or that were treated with 10 injections of mouse monoclonal IgG1 (MOPC 21) (MO19) and of mice treated with 
10 injections of LTR-Ig (LT19). Bars = 100 m. (b) Proportion of B-cell zones to the total area of the gland (that is, the B-cell ratio index). (c) Pro-
portion of T-cell zones to the total area of the gland (that is, the T-cell ratio index). (d) Number of HEVs to the total area of the gland. Each of the 10 
groups had three or four randomly selected mice for each staining and analysis. Legend applies to frames (b-d). Bars indicate the mean and the 
standard error of the mean.Page 6 of 12
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the levels recorded in the NT9 group (Figure 5a). This phe-
nomenon did not occur in either the MO19 or the NT19 group.
There was a statistically significant main effect on the saliva
flow rate of the number of injections administered (P = 0.042).
The saliva flow rates of the MO19 and LT19 groups were sig-
nificantly different (P = 0.049). To determine whether the
hyperglycemic state of the mice influenced the saliva flow
rates, we compared the saliva flow rates in mice within the
same group with either low or high glucose levels and found
no significant differences (data not shown).
Cytokines in saliva samples
Interleukin (IL)-1-beta was detected in all of the samples ana-
lyzed (from 55 individual mice), whereas vascular endothelial
growth factor was detected in all but one of the samples. For
macrophage inflammatory protein-1 alpha (MIP-1), IL-10, IL-
2, and IL-1, samples with a mean fluorescent intensity corre-
sponding to a value lower than the least detectable concentra-
tion were assigned values of 0. Basic fibroblast growth factor
and CXCL10 were each detected in only one of the samples.
The other cytokines/chemokines tested (that is, granulocyte
macrophage-colony stimulating factor, interferon-gamma, IL-4,
IL-5, IL-12, IL-13, IL-17, CXCL1, CCL2, CXCL9, and TNF-)
were not detected in any of the samples. There was a striking
Figure 3
Effect of lymphotoxin-beta receptor-immunoglobulin fusion protein (LTR-Ig) treatment on follicular dendritic cell (FDC) networks and chemokines. 
(a) Photomicrographs of immunohistochemical staining for FDC networks and CXCL13 and CCL19 in the submandibular glands. Three or four mice 
from each of the 10 groups were randomly selected for immunohistochemistry. Data shown here are representative examples of control mice (19 
weeks old) that were not treated (NT19) or that were treated with 10 injections of mouse monoclonal IgG1 (MOPC 21) (MO19) and of mice treated 
with 10 injections of LTR-Ig. Arrowheads indicate sites of chemokine staining. Bars = 100 m. A comparison of relative mRNA expressions of 
CXCL13 (b), CCL19 (c), and CCL21 (d) in salivary glands of the baseline group (NT9 group) and the oldest mice (19 weeks old) treated with either 
LTR-Ig or MOPC 21 or untreated. Salivary glands from seven or eight mice per group were used in this analysis. Quantitative polymerase chain 
reactions (Q PCRs) using RNA from each organ were run in quadruplicate, and the mean signal was normalized to the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Data are presented as the mean of the values for the replicate organs (seven or eight organs per point) and the standard 
deviation. The differences between LT19 and controls were not significant.Page 7 of 12
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NT9 groups. High levels of saliva cytokines (both pro- and anti-
inflammatory) were observed in the NT16 group. The results of
the analysis of the pro- and anti-inflammatory cytokines are
shown in Figure 5b.
Serum LTR-Ig levels decrease as the mice age
The serum levels of LTR-Ig were determined 1 week after the
final LTR-Ig injection in each group. A more-than-twofold
drop in the LTR-Ig levels was observed in older mice (88.19
± 12.04 and 40.17 ± 8.87 g/mL in 12-week-old and 19-
week-old mice, respectively).
Effect of mouse monoclonal IgG1
An effect of MOPC 21 was observed. However, except for
expression levels of MO19 and NT19 CCL21b mRNA (P =
0.042), the levels of the various parameters studied in MOPC
21 mice were not significantly different from those of the
untreated mice.
Discussion
The results disclosed that blocking the LTR pathway in NOD
mice not only has an effect on the blood glucose levels, as
reported previously [23,25], but also has profound effects on
the salivary gland lesion, a hallmark of SS-like disease in NOD
mice. The loss of FDC networks on blocking the LTR path-
way in adult mice has been described previously [19,34], but
the present study is the first to report that LTR-Ig treatment
results in FDC network loss in the salivary glands. FDC net-
works constitutively release a substantial amount of CXCL13
[35], although there are other sources of CXCL13, such as
macrophages, dendritic cells, and primed follicular helper T
cells [35]. CXCL13 recruits B cells and follicular helper T cells
to the B-cell zones. Immunohistochemistry disclosed that both
LTR-Ig-treated mice and controls expressed CXCL13 at the
protein level in the salivary glands. There was, however, a
depletion of B-cell zones by 19 weeks (LT19 group). This was
probably attributable to the reduction in the amount of
CXCL13, as indicated by the reduction in CXCL13 mRNA
expression levels in the LT19 group compared with controls.
Figure 4
Immunohistochemical analysis of lymph nodes. Mandibular lymph nodes from two to six mice per group were examined (multiple lymph nodes in 
some mice). Representative photomicrographs of immunohistochemical staining of lymph nodes from mice from the LT12 group and NT12 group. 
For the follicular dendritic cell (FDC) network panels, the LT12 lymph node has no FDC networks, but B cells are picked by the CD21 antibody, and 
the NT12 lymph node has prominent FDC networks. Original magnifications: × 50 (insets), × 400 (CCL19), and × 200 (all other images).Page 8 of 12
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ment may also have contributed to the lack of B-cell zones in
the LT19 group.
There was also an all-out loss of HEVs in the salivary glands in
the LT16 and LT19 groups. HEVs exhibit specific address sig-
nals that are recognized by circulating lymphocytes. PNAd is
one such signal (antigen) that was first defined by reactivity
with monoclonal antibody MECA-79 [36]. L-selectin on the cir-
culating lymphocytes binds carbohydrate epitopes of PNAd,
facilitating homing of these naïve lymphocytes [37]. Previous
studies have reported a prominent role for the LTR pathway
in maintaining the HEV structures in a functional state in lymph
nodes of adult mice [13,33] and in sites of lymphoid neogen-
esis [38]. The LTR pathway is also important in de novo lym-
phangiogenesis in sites of lymphoid neogenesis [39].
Although the mRNA expression levels of CCL19 were not sig-
nificantly reduced in the LTR-Ig-treated mice, there was a
complete loss of CCL19 protein in the salivary gland infiltrates
of LTR-Ig-treated mice. CCL19 and CCL21 are necessary
for the transmigration of naïve T cells and central memory T
cells across the HEVs and in the formation of T-cell zones [40].
Therefore, the combination of ablation of FDC networks, loss
of HEVs, and reduced chemokine expression would ultimately
result in a reduced influx of B and T cells to the salivary glands.
This may explain the reduced B- and T-cell zones in the LTR-
Ig-treated mice.
Another interesting observation was the different response to
LTR-Ig treatment by the salivary gland lesion and the draining
lymph nodes. There is no consensus as to which of these sites
drives the immune response or whether there is a contribution
from both [13]. Our findings indicate that the LTR-Ig treat-
ment had a more profound effect on the microarchitecture of
the salivary gland lymphoid tissue than on that of the lymph
node.
Our findings also suggest that the salivary gland lesion has a
prominent role in SS-like disease, as partial saliva flow resto-
Figure 5
Salivary gland function and saliva cytokine analysisi l i . (a) Saliva flow rates of the 10 groups. The saliva flow rate was expressed as microliters of saliva 
secreted per minute per gram of mouse body weight. Data were analyzed by one-way analysis of variance followed by Tukey post hoc test. *P < 
0.05, **P < 0.01, and ***P < 0.001 indicate statistically significant differences between the specific group and the NT9 group. Horizontal lines indi-
cate the mean. Symbols refer to individual mice treated with lymphotoxin-beta receptor-immunoglobulin fusion protein (LTR-Ig) (), mouse mono-
clonal IgG1 (MOPC 21) (❍), or no treatment (). Each symbol indicates data from one mouse. (b) Heat map of saliva cytokines showing fluctuations 
in the levels of cytokines in the control mice groups and LTR-Ig-treated mice over time. The mean cytokine level of each mouse group was deter-
mined and Z-score standardization was computed for each cytokine using SPSS version 15.0. The heat map was drawn in Excel® 2003. IL, inter-
leukin; MIP-1, macrophage inflammatory protein-1 alpha; VEGF, vascular endothelial growth factor.Page 9 of 12
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the salivary gland. The ectopic lymphoid tissue has a promi-
nent role in several diseases/conditions [13]. In the NOD
mouse, pancreatic lymphoid neogenesis could initiate and
sustain the progression of IDDM in the absence of draining
lymph nodes [41]. Interestingly, it has been proposed that
LTR-Ig treatment would result in a quiescent state of the
lymph nodes, draining the sites of inflammation [13]. This is
partly supported by the present study, showing microarchitec-
tural differences between LTR-Ig-treated mice and control
lymph nodes. However, the lymph node microarchitectural
changes in our experimental setup are unlike the grossly dis-
turbed primary or secondary organ development observed in
mice deficient in components of the LTR pathway.
The present study was based on the hypothesis that LTR-Ig
treatment would preserve the integrity of the salivary gland by
preventing development and progression of inflammation and
lymphoid neogenesis, thus preventing the occurrence of sali-
vary gland dysfunction. Our results, however, show that LTR-
Ig treatment may reverse pathological events that have already
occurred in the salivary gland. This possibility is underscored
by the finding of HEVs in the salivary glands of 12-week-old
mice given three LTR-Ig injections (although in only one
mouse) but loss of HEVs in 16-week-old and 19-week-old
mice treated with LTR-Ig. Earlier analyses in mice suggested
that a period of at least 2 weeks of LTR-Ig treatment was
required to downmodulate HEVs and therefore any early HEVs
could still be present at week 12 [33]. Also, the saliva flow rate
appeared to fall (comparing LT12 and LT16 groups) but
recovered in the LT19 group, indicating that the salivary gland
dysfunction may have been prevented or reversed.
The dichotomous distribution of saliva flow rates in NOD mice
has been described previously [42]. The same study also used
saliva proteins to describe the efficacy of intervention agents
in SS-like disease of NOD mice. In our study, the striking sim-
ilarity in the cytokine profiles of the pre-disease NT9 group and
the LT19 group may indicate a restoration of the pre-disease
quality of saliva in the LT19 group. However, analysis of pro-
and anti-inflammatory cytokines and chemokines in saliva from
untreated mice across different ages disclosed no obvious
trend indicative of progressive disease status. However, 16
weeks may mark a time of potentially heightened cytokine pro-
duction and activity in the NOD mouse.
Accelerated clearance of immunoglobulin-based agents is
commonly observed in many rodent autoimmune disease mod-
els, and our finding of a reduction in the serum levels of LTR-
Ig as the mice age also points to a possible increased clear-
ance of the fusion protein in these older NOD mice. It is pos-
tulated that, had the high levels of LTR-Ig observed in 12-
week-old mice been sustained throughout the experiment, the
protective/reversal effects of LTR-Ig would have been more
pronounced.
There are severe technical limitations to finding proper con-
trols for fusion proteins when faced with the need to use high-
level dosing in autoimmune disease models to maintain cover-
age. A protective effect of polyclonal human IgG used as a
control protein in experiments to determine the efficacy of
LTR-Ig in collagen-induced arthritis was reported [34]. The
mechanism behind the MOPC 21 effect may involve non-spe-
cific binding of MOPC 21 to targets in the pathways involved
in the disease process, resulting in a protective effect.
The immune dysregulation occurring in the female NOD back-
ground leads to autoreactivity and inflammation of the salivary
glands. This inflammation is accompanied by the formation of
lymphoid tissues in the salivary glands with HEVs and FDC
networks. Although the role of these tertiary lymphoid tissues
in the pathogenesis remains unclear, the present study clearly
demonstrates that LTR inhibition, whether via its effects on
trafficking or lymphoid architecture, results in a less destruc-
tive environment in the target organ.
Conclusion
This study shows that blocking the LTR pathway in NOD
mice ablates lymphoid neogenesis in the salivary glands and
this is accompanied by an improvement in salivary gland func-
tion. To our knowledge, the effect of interfering with the LTR
axis has not previously been explored in SS-like disease. It is
hoped that our results will contribute to the development of
appropriate methods for treatment of human SS.
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